within Pharmacolibrary.Drugs.ATC.N;

model N06DA02
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.99,
    Cl             = 2.166666666666667e-06,
    adminDuration  = 600,
    adminMass      = 5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0121,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0032166666666666667,
    Tlag           = 600,            
    Vdp             = 0.0079,
    k12             = 0.023,
    k21             = 0.023
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N06DA02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Donepezil is an acetylcholinesterase inhibitor used to treat symptoms of Alzheimer's disease by increasing levels of acetylcholine in the brain. It is approved and widely used today as a first-line medication for mild to moderate dementia of the Alzheimer's type.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after single oral administration of 5 mg donepezil.</p><h4>References</h4><ol><li><p>Tariot, PN, et al., &amp; Oh, C (2022). Comparison of Steady-State Pharmacokinetics of Donepezil Transdermal Delivery System with Oral Donepezil. <i>Journal of Alzheimer&#x27;s disease : JAD</i> 90(1) 161–172. DOI:<a href=\"https://doi.org/10.3233/JAD-220530\">10.3233/JAD-220530</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36120781/\">https://pubmed.ncbi.nlm.nih.gov/36120781</a></p></li><li><p>Agrawal, M, et al., &amp; Alexander, A (2018). Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs. <i>Journal of controlled release : official journal of the Controlled Release Society</i> 281 139–177. DOI:<a href=\"https://doi.org/10.1016/j.jconrel.2018.05.011\">10.1016/j.jconrel.2018.05.011</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29772289/\">https://pubmed.ncbi.nlm.nih.gov/29772289</a></p></li><li><p>Braeckman, R, &amp; Oh, C (2023). A study of once-a-week donepezil transdermal system&#x27;s bioequivalence to oral donepezil in healthy volunteers: a plain language summary. <i>Neurodegenerative disease management</i> 13(6) 303–313. DOI:<a href=\"https://doi.org/10.2217/nmt-2023-0012\">10.2217/nmt-2023-0012</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37671720/\">https://pubmed.ncbi.nlm.nih.gov/37671720</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N06DA02;
